Cardax(OTC) CDXI

Cardax, Inc. is a biopharmaceutical company dedicated to developing nutritional supplements and pharmaceutical treatments targeting inflammation and oxidative stress. The company’s flagship product, ZanthoSyn, is an advanced supplement designed to enhance health and longevity through superior absorption of astaxanthin.

Products and Services

• ZanthoSyn: A premium supplement for inflammation and health
• CDX-101: A drug candidate for cardiovascular inflammation
• CDX-301: A zeaxanthin-based treatment for macular degeneration

Growth Outlook

• Expansion of online sales channels is anticipated to boost revenue
• Ongoing development of CDX-101 and CDX-301 may enhance market position
• Increasing awareness of inflammation-related health issues supports product demand

Financial Highlights

• Recent quarterly revenue of $104,574 shows potential for growth
• Gross profit margin of 63.3% indicates strong product demand
• Net income for the latest quarter was -$1,820,403, reflecting ongoing investment in R&D

Cardax, Inc. operates in the healthcare sector, focusing on innovative solutions for chronic health issues. The company is headquartered in Honolulu, Hawaii, and employs a small team dedicated to advancing its product offerings. The financial data indicates a challenging environment, with significant net losses, but the gross profit margin suggests that the products are well-received in the market. The ongoing development of pharmaceutical candidates CDX-101 and CDX-301 may provide future revenue streams, aligning with the growing focus on health and wellness. As the company continues to navigate its financial landscape, the potential for growth remains, particularly with the increasing consumer interest in inflammation management and nutritional supplements.